Publication Name	World Journal of Diabetes
Manuscript ID	16507
Country	Norway

Received	2015-01-21 09:33
Peer-Review Started	2015-01-22 08:24
To Make the First Decision	2015-03-06 10:14
Return for Revision	2015-03-14 20:40
Revised	2015-03-28 02:57
Second Decision	2015-07-15 17:24
Accepted by Journal Editor-in-Chief	2015-07-16 16:53
Accepted by Company Editor-in-Chief	2015-07-23 17:00
Articles in Press	2015-07-23 17:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-08-04 15:59
Publish the Manuscript Online	2015-08-14 18:01

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Editorial
Article Title	Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach
Manuscript Source	Invited Manuscript
All Author List	Odd Erik Johansen
Funding Agency and Grant Number
Corresponding Author	Odd Erik Johansen, MD, PhD, Medical Director, Boehringer Ingelheim Norway KS, P.O. Box 405, 1373 Asker, Norway. odd_erik.johansen@boehringer-ingelheim.com
Key Words	Type 2 diabetes; Pharmaceutical; Risk reduction; Outcomes; Cardiovascular
Core Tip	Vasculopathy and cardiovascular (CV) mani-festations in patients with type 2 diabetes differ dependent on disease duration. This literature review supports that it is necessary to contextualize results of CV outcome trials in diabetes to diabetes duration as well as duration and mode of action of the intervention, which may be of particular relevance for those inter-ventions that primarily target pathways related to atherosclerotic processes, organ-remodelling, or vessel integrity. Several CV outcome trials testing newer therapy classes (i.e., di-peptidyl peptidase-4 inhibitors, glucagon-like protein-1 receptor analogues and sodium glucose co-transporter-2 inhibitors) are now due to report and a multiaxial approach to interpret these results is needed.
Publish Date	2015-08-14 18:01
Citation	Johansen OE. Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach. World J Diabetes 2015; 6(9): 1092-1096
URL	http://www.wjgnet.com/1948-9358/full/v6/i9/1092.htm
DOI	http://dx.doi.org/10.4239/wjd.v6.i9.1092

Full Article (PDF)	WJD-6-1092.pdf
Full Article (Word)	WJD-6-1092.doc
Manuscript File	16507-Review.doc
Answering Reviewers	16507-Answering reviewers.pdf
Audio Core Tip	16507-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	16507-Conflict-of-interest statement.pdf
Copyright License Agreement	16507-Copyright assignment.pdf
Peer-review Report	16507-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	16507-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	16507-Scientific misconduct check.pdf
Scientific Editor Work List	16507-Scientific editor work list.pdf